5Y Capital

Signet Therapeutics is a biopharmaceutical startup focusing on developing innovative targeted cancer drugs using novel disease models.

Taimei Technology specializes in developing cloud-based software solutions for clinical research and pharmacovigilance, aimed at enhancing efficiency in the biopharmaceutical industry. Founded in 2013 and headquartered in Jiaxing, China, the company offers a wide array of integrated solutions, including electronic data collection, drug randomization, electronic patient-reported outcomes, and medical imaging systems. Its platform supports collaboration among sponsors, clinical sites, contract research organizations (CROs), patients, and regulatory bodies, facilitating comprehensive clinical trial management and drug monitoring. Taimei Technology also provides additional services such as training, consulting, and outsourcing, catering to the needs of pharmaceutical companies and clinical research organizations. With offices in Shanghai and Beijing, Taimei Technology is dedicated to advancing the clinical research landscape through innovative technology.

Redesign Science Inc is a biotechnology company based in New York, established in 2017, that specializes in small molecule drug discovery. The company employs advanced techniques, including first-principles physics and artificial intelligence, to simulate protein targets at the atomic level. This approach allows Redesign Science to identify subtle drug opportunities that conventional computational models may overlook. By focusing on the development of first-in-class small molecules, the company aims to address emerging and challenging targets associated with significant unmet medical needs. Their innovative methodologies not only enhance the understanding of biological pathways and disease mechanisms but also drive the commercialization of new therapeutic solutions.

Taimei Technology specializes in developing cloud-based software solutions for clinical research and pharmacovigilance, aimed at enhancing efficiency in the biopharmaceutical industry. Founded in 2013 and headquartered in Jiaxing, China, the company offers a wide array of integrated solutions, including electronic data collection, drug randomization, electronic patient-reported outcomes, and medical imaging systems. Its platform supports collaboration among sponsors, clinical sites, contract research organizations (CROs), patients, and regulatory bodies, facilitating comprehensive clinical trial management and drug monitoring. Taimei Technology also provides additional services such as training, consulting, and outsourcing, catering to the needs of pharmaceutical companies and clinical research organizations. With offices in Shanghai and Beijing, Taimei Technology is dedicated to advancing the clinical research landscape through innovative technology.

ASLAN Pharmaceuticals is a clinical-stage biopharmaceutical company based in Singapore, specializing in immunology and oncology. Founded in 2010, the company focuses on developing innovative treatments aimed at improving patient outcomes. Its clinical portfolio includes ASLAN004, a monoclonal antibody therapy for atopic dermatitis and other immunological conditions, as well as small molecule inhibitors targeting various cancer types. ASLAN collaborates with notable partners such as Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL Limited to enhance its research and development efforts. The company is dedicated to creating novel medicines for both Asian and global markets.

DNAtrix, Inc. is a clinical stage biotechnology company based in Houston, Texas, specializing in virus-driven immunotherapies for cancer treatment. The company develops modified viruses designed to selectively target and kill cancer cells, with its lead product, DNX-2401, focused on glioblastoma, an aggressive and currently incurable brain tumor. This oncolytic immunotherapy has shown promising early results, having been administered to over 35 patients. In addition to DNX-2401, DNAtrix is advancing other therapies, including DNX-2440 and DNX-2450 for solid tumors, and MYX-135 for hematological malignancies. The company aims to expand its platform technology to address a broader range of cancers, including brain metastases, ovarian, and pancreatic cancer. DNAtrix has formed a strategic partnership with Valo Therapeutics to enhance its research and development efforts.

Argos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83 soluble protein for transplant rejection/autoimmune disorders; Anti IFN-alpha monoclonal antibody2 for lupus; and regulatory T cell therapy3 for autoimmune disorders. The company was formerly known as MERIX Bioscience, Inc. Argos Therapeutics was founded in 1997 and is based in Durham, North Carolina.

ASLAN Pharmaceuticals is a clinical-stage biopharmaceutical company based in Singapore, specializing in immunology and oncology. Founded in 2010, the company focuses on developing innovative treatments aimed at improving patient outcomes. Its clinical portfolio includes ASLAN004, a monoclonal antibody therapy for atopic dermatitis and other immunological conditions, as well as small molecule inhibitors targeting various cancer types. ASLAN collaborates with notable partners such as Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL Limited to enhance its research and development efforts. The company is dedicated to creating novel medicines for both Asian and global markets.